Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Interventional × Invasive Bladder Cancer × Cystectomy × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Urinary Bladder Neoplasms 35 Carcinoma, Transitional Cell 3 Infiltrating Bladder Urothelial Carcinoma 2 Carcinoma, Renal Cell 2 Urologic Neoplasms 1 Urologic Diseases 1 Urinary Bladder Diseases 1 Ureteral Neoplasms 1 Transitional Cell Carcinoma of the Bladder 1 Transitional Cell Bladder Cancer 1 Stage 0is Bladder Urothelial Carcinoma 1 Prostatic Neoplasms 1 Parkinson Disease 4, Autosomal Dominant Lewy Body 1 Non-metastatic Muscle Invasive Bladder Cancer 1 Muscle Invasive Bladder Cancer 1 Invasive Bladder Cancer 1 Ileus 1 Cone Dystrophy 3 1 Bladder Adenocarcinoma 1 Adrenal Gland Neoplasms 1

Interventions

tremelimumab 1 durvalumab 1 Sodium Chloride 1 Radiotherapy 1 Lidocaine 1 Hyperthermic Intraperitoneal Chemotherapy 1 Cystectomy 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT02924480 2022-03-09

Lidocaine

CAMC Health System

Phase NA Completed

Invasive Bladder Cancer

Data powered by HemOnc (CC BY 4.0) Colophon ⚡